Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin‐3 down‐regulation

Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin‐3 down‐regulation

Abstract Background A global consensus on the loss of skeletal muscle mass and function in humans refers as sarcopenia and cachexia including diabetes, obesity, renal failure, and osteoporosis. Despite a current improvement of sarcopenia or cachexia with exercise training and supportive therapies, a...

Full description

Bibliographic Details
Main Authors: Hsien‐Chun Chiu, Chen‐Yuan Chiu, Rong‐Sen Yang, Ding‐Cheng Chan, Shing‐Hwa Liu, Chih‐Kang Chiang
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Alendronate
Skeletal muscle
Atrophy
Dysfunction
Sirtuin3
Online Access:https://doi.org/10.1002/jcsm.12289

Similar Items

Similar Items